I agree that this site is using cookies. You can find further informations here.
X
Pratz, Keith W
60  results:
OpenAccess-fulltext X
Search for persons X
?
1

Recent advances in targeted therapies in acute myeloid leuk..:

Bhansali, Rahul S ; Pratz, Keith W ; Lai, Catherine
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039574/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

Venetoclax combinations delay the time to deterioration of ..:

Pratz, Keith W ; Panayiotidis, Panayiotis ; Recher, Christian...
qt1k1196kn.  , 2022
Link: https://escholarship.org..
 
?
3

Optimizing outcomes in secondary AML:

Matthews, Andrew ; Pratz, Keith W
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820930/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
4

Outcomes in Patients with Poor-Risk Cytogenetics with or wi..:

Pollyea, Daniel A ; Pratz, Keith W ; Wei, Andrew H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751752/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
5

Outcomes in Patients With Poor-risk Cytogenetics With or Wi..:

Pollyea, Daniel A ; Pratz, Keith W ; Wei, Andrew H...
qt14k765pj.  , 2022
Link: https://escholarship.org..
 
?
6

Measurable Residual Disease Response and Prognosis in Treat..:

Pratz, Keith W ; Jonas, Brian A ; Pullarkat, Vinod...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906463/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
7

Real-world effectiveness of CPX-351 vs venetoclax and azaci..:

Matthews, Andrew H ; Perl, Alexander E ; Luger, Selina M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278286/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
8

Postremission cytopenia management in patients with AML tre..:

Pratz, Keith W ; DiNardo, Courtney D ; Selleslag, Dominik...
info:eu-repo/semantics/altIdentifier/pmid/36054316.  , 2022
Link: http://hdl.handle.net/21..
 
?
9

Impact of FLT3 Mutation on Outcomes after Venetoclax and Az..:

Konopleva, Marina ; Thirman, Michael J ; Pratz, Keith W...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365380/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 ..:

Pratz, Keith W ; Kaplan, Jason ; Levy, Moshe...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973464/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Measurable Residual Disease Response and Prognosis in Treat..:

Pratz, Keith W ; Jonas, Brian A ; Pullarkat, Vinod...
qt3wh7c0cz.  , 2022
Link: https://escholarship.org..
 
?
12

Use of CYP3Ai and impact on outcomes in patients with acute..:

Jonas, Brian A ; DiNardo, Courtney ; Fracchiolla, Nicola...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286746/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Measurable Residual Disease Response and Prognosis in Treat..:

Pratz, Keith W ; Jonas, Brian A ; Pullarkat, Vinod...
Journal Of Clinical Oncology. -40 : 8 (2022), p. 855-865. -J. Clin. Oncol. - 0732-183X. - 1527-7755.  , 2022
Link: http://hdl.handle.net/24..
 
?
14

Cost-Effectiveness Analysis of Venetoclax in Combination wi..:

Pratz, Keith W ; Chai, Xinglei ; Xie, Jipan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300490/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

Targeting Menin and CD47 to Address Unmet Needs in Acute My..:

Matthews, Andrew H ; Pratz, Keith W ; Carroll, Martin P
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735817/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15